Gnubiotics Sciences

About Gnubiotics Sciences

❌❓ THE CHALLENGE: Glycans hide the tumor in disguise. ➡ Typical cancer-specific Tumor Glycocodes render the tumor invisible to the immune system, they stay ‘cold’. Intelligently, glycans from that Tumor Glycocode are not present on neighbouring healthy tissue, rendering it a perfect target for eradication & potential use as biomarker for patient selection and treatment response. ➡ So far, efforts to break that code for therapeutic benefits have been unsuccessful. One reason for this is the dynamic shape & motion of glycans, and the inability to manufacture them ex vivo. ⭕❗ THE SOLUTION: Conjugated Glycopeptides. Gnubiotics’ proprietary technology conjugates O-glycans with short protein parts - peptides - ex vivo to form novel glycopeptides that are druggable targets amenable to mass production. 🔜 Breaking the Tumor Glycocode. Since 2019, multiple preclinical models have demonstrated proof of concept for the lead compound GNU101 to be orally bioavailable, resisting degradation, and surviving enzyme proteolysis. The preclinical body of evidence has demonstrated proof-of-concept that the GENESIS platform based glycopeptides are able to turn 'cold' into 'hot' tumors, breaking through I/O resistance and inducing tumor cell killing. 💡 THE TEAM: We are a highly specialized team of Founders, Scientists and Entrepreneurs pursuing the transition from a large basis of preclinical evidence into IND-readiness and the clinics with First-in-human clinical phase 1 study for colorectal cancer patients in 2024/2025. 📥 Curious to learn more? Check out our new website and contacts 🌐 https://gnubiotics.com/

View contact profiles from Gnubiotics Sciences